Advances in Psychiatry 3
January 29, 2022 @ 9:00 am - 12:15 pm PST
Advances In Psychiatry III
New Developments in Psychedelic Research and Treatment
ONLINE: Saturday, January 29, 2022
9:00 A.M. – 12:15 P.M.
REGISTRATION IS NOW CLOSED FOR THIS EVENT
9:00am – 10:30am
Psychedelics and Psychiatry: A New Treatment Model for the 21st Century
Charles Grob, M.D.
Professor of Psychiatry and Bio-Behavioral Sciences and Pediatrics, David Geffen School of Medicine at UCLA; Director, Division of Child and Adolescent Psychiatry, Harbor-UCLA Medical Center; Investigator,
Lundquist Research Institute
This presentation will demonstrate how the psychedelic treatment model represents a paradigm shift in the conceptualization and treatment of psychiatric disorders. An overview of modern clinical research findings with MDMA and psilocybin will help to clarify emerging perspectives with broad potential implications for the future of psychiatry. The role of recent developments in public opinion conjoined with an evolving legal landscape in regard to hallucinogens will be addressed as they impact current research endeavors. The presentation will conclude with all important attention to optimizing safety and ethical parameters for clinical research with hallucinogenic drugs. The presentation will close with a Q and A with the audience.
10:40am – 12:15pm
Psilocybin Therapy in Palliative Care
Brian Anderson, MD, MSc
Zuckerberg San Francisco General Hospital; UCSF Department of Psychiatry and Behavioral Sciences
The field of psilocybin research has expanded rapidly over the last 5 years with new clinical trials for a variety of indications being initiated on a regular basis. There is also a growing interest in regulatory alternatives that are making Psilocybin mushrooms and other psychedelics more readily available in the US. Given this growing interest in these substances, there is an ever more urgent need for robust and reliable information on the safety and potential efficacy of psilocybin. Over the last several decades, treating existential distress in patients with serious medical illness has consistently been a leading indication for psychedelic therapies. This talk will explore 20th and 21st Century data on the use of psilocybin for mood, anxiety, and existential distress in clinical populations, with a focus on palliative care patients. We will focus on the limitations of current data, health risks and contraindications, and an evaluation of how the potential benefits of psilocybin therapy compare to currently available interventions.
Registration is Now Closed
SCPS Members $40.00 | Non-SCPS Members $65.00
SCPS Resident-Fellow Members $10.00 | Non-Member Residents $20.00
CME is not available for this event
Cancellations must be received 72 hours prior to the meeting and will be assessed a $15 administrative processing fee.